https://consumer.healthday.com/subcutaneous-mab-benefits-outpatients-with-mild-moderate-covid-2657132349.html
0
0
4/12/22 at 3:06pm
Organization
Healthday.com
Author
Physician’s Briefing Staff
34 words
0
Comments
SC casirivimab and imdevimab linked to reduced 28-day hospitalization or death for high-risk outpatients with mild to moderate COVID-19
You are the first to view
Create an account
or login to join the discussion